Grape King Bio Ltd (1707.TW)
TWD 151.0
(0.0%)
TWD 151.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 192.92 Million TWD | 22.29% |
| 2022 | 157.75 Million TWD | -41.95% |
| 2021 | 271.75 Million TWD | -86.96% |
| 2020 | 2.08 Billion TWD | 55.18% |
| 2019 | 1.34 Billion TWD | 19.85% |
| 2018 | 1.12 Billion TWD | 8.89% |
| 2017 | 1.02 Billion TWD | -26.05% |
| 2016 | 1.39 Billion TWD | -44.59% |
| 2015 | 2.51 Billion TWD | 39197.09% |
| 2014 | 6.39 Million TWD | -52.3% |
| 2013 | 13.39 Million TWD | -17.34% |
| 2012 | 16.2 Million TWD | -76.44% |
| 2011 | 68.8 Million TWD | 8.01% |
| 2010 | 63.69 Million TWD | -72.67% |
| 2009 | 233.1 Million TWD | 6.0% |
| 2008 | 219.92 Million TWD | 6.8% |
| 2007 | 205.91 Million TWD | -34.61% |
| 2006 | 314.89 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 185.79 Million TWD | -3.69% |
| 2024 Q2 | 183.47 Million TWD | -1.25% |
| 2023 Q1 | 146.76 Million TWD | -6.96% |
| 2023 Q3 | 205.11 Million TWD | -4.72% |
| 2023 Q2 | 215.26 Million TWD | 46.67% |
| 2023 FY | 192.92 Million TWD | 22.29% |
| 2023 Q4 | 192.92 Million TWD | -5.94% |
| 2022 FY | 157.75 Million TWD | -41.95% |
| 2022 Q1 | 172.29 Million TWD | -36.6% |
| 2022 Q4 | 157.75 Million TWD | -16.15% |
| 2022 Q3 | 188.14 Million TWD | -5.43% |
| 2022 Q2 | 198.95 Million TWD | 15.47% |
| 2021 Q1 | 368.56 Million TWD | -82.31% |
| 2021 FY | 271.75 Million TWD | -86.96% |
| 2021 Q3 | 372.12 Million TWD | 4.1% |
| 2021 Q4 | 271.75 Million TWD | -26.97% |
| 2021 Q2 | 357.48 Million TWD | -3.01% |
| 2020 FY | 2.08 Billion TWD | 55.18% |
| 2020 Q1 | 1.51 Billion TWD | 12.97% |
| 2020 Q2 | 1.38 Billion TWD | -8.86% |
| 2020 Q3 | 2.2 Billion TWD | 59.82% |
| 2020 Q4 | 2.08 Billion TWD | -5.69% |
| 2019 Q1 | 1.46 Billion TWD | 30.37% |
| 2019 Q2 | 796.07 Million TWD | -45.51% |
| 2019 Q3 | 1.53 Billion TWD | 92.27% |
| 2019 Q4 | 1.34 Billion TWD | -12.26% |
| 2019 FY | 1.34 Billion TWD | 19.85% |
| 2018 FY | 1.12 Billion TWD | 8.89% |
| 2018 Q4 | 1.12 Billion TWD | -4.77% |
| 2018 Q3 | 1.17 Billion TWD | 43.95% |
| 2018 Q2 | 817.4 Million TWD | -26.28% |
| 2018 Q1 | 1.1 Billion TWD | 7.74% |
| 2017 Q1 | 1.1 Billion TWD | -20.93% |
| 2017 FY | 1.02 Billion TWD | -26.05% |
| 2017 Q4 | 1.02 Billion TWD | -1.37% |
| 2017 Q2 | 1.09 Billion TWD | -0.66% |
| 2017 Q3 | 1.04 Billion TWD | -4.55% |
| 2016 Q1 | 2.46 Billion TWD | -2.01% |
| 2016 FY | 1.39 Billion TWD | -44.59% |
| 2016 Q3 | 1.39 Billion TWD | -34.55% |
| 2016 Q4 | 1.39 Billion TWD | -0.34% |
| 2016 Q2 | 2.13 Billion TWD | -13.31% |
| 2015 Q3 | 2.55 Billion TWD | 41.1% |
| 2015 FY | 2.51 Billion TWD | 39197.09% |
| 2015 Q4 | 2.51 Billion TWD | -1.54% |
| 2015 Q2 | 1.8 Billion TWD | 24710.64% |
| 2015 Q1 | 7.28 Million TWD | 14.0% |
| 2014 Q4 | 6.39 Million TWD | -40.22% |
| 2014 Q2 | 8.75 Million TWD | -0.16% |
| 2014 Q1 | 8.76 Million TWD | -34.55% |
| 2014 FY | 6.39 Million TWD | -52.3% |
| 2014 Q3 | 10.69 Million TWD | 22.11% |
| 2013 Q4 | 13.39 Million TWD | 52.53% |
| 2013 Q3 | 8.78 Million TWD | -30.57% |
| 2013 Q2 | 12.65 Million TWD | 5.29% |
| 2013 Q1 | 12.01 Million TWD | -25.87% |
| 2013 FY | 13.39 Million TWD | -17.34% |
| 2012 Q1 | 71.11 Million TWD | 3.36% |
| 2012 FY | 16.2 Million TWD | -76.44% |
| 2012 Q2 | 65.22 Million TWD | -8.28% |
| 2012 Q3 | 65.51 Million TWD | 0.44% |
| 2012 Q4 | 16.2 Million TWD | -75.26% |
| 2011 Q2 | 64.19 Million TWD | -14.52% |
| 2011 FY | 68.8 Million TWD | 8.01% |
| 2011 Q1 | 75.1 Million TWD | 17.91% |
| 2011 Q4 | 68.8 Million TWD | -9.47% |
| 2011 Q3 | 76 Million TWD | 18.38% |
| 2010 FY | 63.69 Million TWD | -72.67% |
| 2010 Q4 | 63.69 Million TWD | 0.0% |
| 2009 FY | 233.1 Million TWD | 6.0% |
| 2008 FY | 219.92 Million TWD | 6.8% |
| 2007 FY | 205.91 Million TWD | -34.61% |
| 2006 FY | 314.89 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Standard Chem & Pharm CO., LTD. | 1.08 Billion TWD | 82.17% |
| Maywufa Company Ltd. | 442.66 Million TWD | 56.419% |
| ScinoPharm Taiwan, Ltd. | 621.1 Million TWD | 68.939% |
| Lotus Pharmaceutical Co., Ltd. | 11.58 Billion TWD | 98.335% |
| LIWANLI Innovation Co., Ltd. | 2.63 Million TWD | -7218.665% |
| YungShin Global Holding Corporation | 1.23 Billion TWD | 84.435% |
| PhytoHealth Corporation | 28.11 Million TWD | -586.182% |
| SCI Pharmtech, Inc. | 1.04 Billion TWD | 81.494% |
| Formosa Laboratories, Inc. | 4.06 Billion TWD | 95.253% |
| PharmaEssentia Corporation | 1.2 Billion TWD | 83.926% |
| Bora Pharmaceuticals Co., LTD. | 5 Billion TWD | 96.149% |